clinical trial

Gilead Says Hepatitis C Patients Had Relapse in Trial, Shares Plunge

Posted February 21st, 2012 by admin
in

Shares of Gilead Sciences (GILD: 44.69, -2.31, -4.91%) fell 14% Friday morning after the drug maker said a majority of patients enrolled in one of its studies experienced a viral relapse within four weeks of completing the 12-week experimental hepatitis C treatment.

Six of the eight patients that previously had a “null” response but were taking GS-7977 plus the widely used antiviral ribavirin as part of Gilead’s Electron study had a relapse.

Some new information on the oral hep c drugs in the pipe line.

Posted January 16th, 2012 by admin
in

Yesterday, January 9, 2012 Inhibitex, makers of an oral hep c drug was purchased by Bristol Myers for 2.5 Billion dollars.

On Squawk Box, CNBC,  Kramer said, I don’t get it, hep c is a horrible disease, it is fatal but not a big deal. He said, I don’t get it, why so much money is being paid for this oral phase 2 asset. Inhibitex stock went up 189 times over night. A terrific profit.

Thanks for the Many Referrals to our Quercetin Study

Posted November 30th, 2011 by admin
in

From: nlu@mednet.ucla.edu [mailto:nlu@mednet.ucla.edu]
Sent: Thursday, November 10, 2011 11:35 PM
To: LloydWright
Subject: [Contact Lloyd] Quercetin Phase I Clinical Trial at UCLA

Nu Lu sent a message using the contact form at http://lloydwright.org/messages/contact.

Hello Mr. Wright,

the road to recovery

Posted November 30th, 2011 by admin
in

From: Jackie
Sent: Friday, October 28, 2011 9:01 AM
To: LloydWright

Subject: Hep c

I'm so happy today. I have taken 3 villas of natcell cf and yesterday I cleaned house all day, first time in a year. Felt good. Also I stated

Rejected for Trial for Patients With Hepatitis C

Posted November 25th, 2011 by admin
in

From:
Sent: Tuesday, October 25, 2011 1:17 PM
To: LLOYD
Subject: FW: ClinicalTrials.gov identifier: NCT01438320

Hi Lloyd,

Thought you might like to see the response I received from the UCLA Study. Maybe you can use this for your out of state customers info.

Thanks,
Tim 

Quercetin Study Recruiting Participants

in
Q-Trial in Patients With Hepatitis C This study is currently recruiting participants. The verification date is the most recent date the responsible party verified the study information is correct. The last updated date is the most recent date the record changed in any way. The two dates may be different."> Verified on September 2011 by University of California, Los Angeles